Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Antiviral Research

• Publication date

  2002-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0166-3542(02)00100-6PMID 12367719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT

  2002cited by this paper
• Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• Cellular immune responses to HIV

  2001cited by this paper
• Relative Dominance of Epitope-Specific Cytotoxic T-Lymphocyte Responses in Human Immunodeficiency Virus Type 1-Infected Persons with Shared HLA Alleles

  2001cited by this paper
• HIV chemotherapy

  2001cited by this paper
• HIV chemotherapy : AIDS

  2001cited by this paper
• Challenges and opportunities for development of an AIDS vaccine

  2001cited by this paper
• Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes

  2000cited by this paper
• Immunogenicity of Mutations Induced by Nucleoside Reverse Transcriptase Inhibitors for Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Cells

  2000cited by this paper
• HIV Resistance to Antagonists of Viral Reverse Transcriptase

  1999cited by this paper
• Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

  1999cited by this paper
• Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

  1999cited by this paper
• Human immunodeficiency viruses in the developing world.

  1999cited by this paper
• A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• HIV resistance to antiviral drugs: public health implications.

  1998cited by this paper
• Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.

  1998cited by this paper
• Cytotoxic T‐cell responses to HIV‐1 reverse transcriptase, integrase and protease

  1998cited by this paper
• Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

  1998cited by this paper
• How immune-based interventions can change HIV therapy

  1997cited by this paper
• Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development

  1997cited by this paper
• Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

  1997cited by this paper
• Mutations in Retroviral Genes Associated with Drug Resistance

  1996cited by this paper
• A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation.

  1996cited by this paper
• Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.

  1996cited by this paper
• Induction of a primary human cytotoxic T‐lymphocyte response against a novel conserved epitope in a functional sequence of HIV‐1 reverse transcriptase

  1995cited by this paper
• Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein.

  1995cited by this paper
• Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1

  1994cited by this paper
• Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein

  1994cited by this paper
• Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

  1994cited by this paper
• Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes.

  1993cited by this paper
• Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein

  1993cited by this paper
• HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate.

  1993cited by this paper
• In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine

  1992cited by this paper
• Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

  1992cited by this paper
• Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein.

  1991cited by this paper
• High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells

  1990cited by this paper
• AIDS And the New Viruses

  1990cited by this paper
• HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals.

  1988cited by this paper

• Avirulins, a Novel Class of HIV-1 Reverse Transcriptase Inhibitors Effective in the Female Reproductive Tract Mucosa

  2019cites this paper
• Genetic Diversity and the Human Immunodeficiency Virus Type-1 : Implications and Impact Orville Heslop

  2012cites this paper
• Genetic Diversity and the Human Immunodeficiency Virus Type-1: Implications and Impact

  2012cites this paper
• Update on HIV-1 diversity in Africa: a decade in review.

  2012cites this paper
• HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes

  2010cites this paper
• Transmitted drug resistance in nonsubtype B HIV-1 infection.

  2009cites this paper
• Analysis of the diversity of the HIV‐1 pol gene and drug resistance associated changes among drug‐naïve patients in Burkina Faso

  2009cites this paper
• Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.

  2009cites this paper
• Trends in the European HIV/AIDS epidemic: a perspective from Italy

  2009cites this paper
• Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2

  2008cites this paper
• Efavirenz – Still First-line King?

  2008cites this paper
• An investigation of the rate of change of CD4 and CD8 T lymphocyte counts and viral loads in HIV infected patients on immune boosters

  2007influential citation
• HIV genetic diversity: biological and public health consequences.

  2007cites this paper
• HIV Subtypes Distribution and Implication for Antiretroviral Treatment in a Ugandan Population

  2007cites this paper
• Investigation of Viral Genetic and Biologic Determinants of HIV-1 Subtype C Predominance in India

  2007cites this paper
• HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture

  2006influential citation
• HIV-1 subtype C viruses rapidly develop K65R

  2006cites this paper
• Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART.

  2005cites this paper
• HIV‐1 subtypes in Spain: a retrospective analysis from 1995 to 2003

  2005cites this paper
• Mutations and Polymorphisms Associated with Antiretroviral Drugs in HIV-1C-Infected African Patients

  2004cites this paper
• Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir

  2004cites this paper
• HIV-1 subtype distribution and the problem of drug resistance

  2004cites this paper
• Is there any hope for AIDS?

  2004cites this paper
• K103N mutation in antiretroviral therapy-naive African patients infected with HIV type 1.

  2004cites this paper
• Résistance du VIH aux antirétroviraux : Conséquences pour les pays à faibles revenus

  2004cites this paper
• [HIV drug resistance and optimization of antiviral treatment in resource-poor countries].

  2004cites this paper
• Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.

  2004cites this paper
• A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

  2003cites this paper
• Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance.

  2003cites this paper